Skip to main content

Indonesia’s Ministry of Health and Philips to deliver nationwide coverage of advanced image-guided therapy systems in Indonesia, expanding access to cardiac, stroke and cancer care in all 38 provinces

Philips Azurion image-guided therapy system

Doctor and patient in Indonesia

July 29, 2025

  • Long-term multiyear agreements will see Philips installing its advanced Azurion image-guided therapy systems nationwide across all provinces, including rural and remote areas
  • Initiative brings minimally invasive care to millions of cardiac, stroke and cancer patients in Indonesia
  • Combines cutting-edge treatment technology, services and training to strengthen Indonesia’s health infrastructure


Amsterdam, the Netherlands and Jakarta, Indonesia –
In a major step toward transforming healthcare delivery, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and the Indonesia’s Ministry of Health today announced plans to deploy state-of-the-art image-guided therapy systems nationwide, as part of their signed agreements, under the Strengthening Indonesia’s Healthcare Referral Network (SIHREN) project.

The landmark agreements, recently awarded to Philips after an international, competitive bidding process, combine cutting-edge treatment technology, services and training to strengthen Indonesia’s health infrastructure. The initiative aims to transform the country’s treatment for heart disease, stroke and cancer – Indonesia’s leading causes of death – by expanding access to cutting-edge technologies and care in all 38 provinces, from Aceh to Papua. This initiative is set to benefit millions of patients across Indonesia. 

The SIHREN project is an ambitious effort jointly funded by the World Bank and other multilateral development banks to support Indonesia’s health transformation agenda by significantly improving referral healthcare.

Challenges in ensuring equitable access to healthcare

With a population exceeding 280 million, Indonesia is the world’s fourth most populous nation. As a vast archipelago of over 17,000 islands, it faces significant challenges in ensuring equitable access to healthcare. The country is also grappling with a surge in non-communicable diseases (NCDs) such as heart disease, stroke and cancer – conditions projected to impose a staggering economic burden of USD 4.47 trillion [1]. And yet, advanced care for these illnesses remains largely centralized on the densely populated island of Java, leaving much of the country underserved.

The initiative will establish a nationwide network of advanced image-guided therapy rooms, dramatically expanding access to minimally invasive treatments across hundreds of hospitals in all 38 provinces. The Ministry of Health has made a long-term commitment to delivering nationwide coverage of the Azurion platform, aligned to local hospital infrastructure and patient population needs.

A study published in the Journal of Minimally Invasive Surgery [2] found that minimally invasive techniques significantly reduce postoperative pain, recovery time, and hospital stays compared to traditional open surgeries.

“Delivering better care for more people requires strong partnerships and the best innovations,” said Roy Jakobs, CEO of Royal Philips. “We’re honored to be Indonesia’s partner of choice to deliver our innovation directly where it’s needed most. More patients in Indonesia will now have access to better care.”

“Minimally invasive care is life-changing for patients, unlocking treatment options that were once unimaginable. With small incisions, such targeted treatments can mean shorter hospital stays, fewer complications and quicker recoveries for patients,” said Carla Goulart Peron, Chief Medical Officer at Philips. “From opening heart-attack-causing blockages, to treating strokes and targeting cancer tumors, image-guided, minimally invasive therapy will be a game-changer for NCD care in Indonesia.”

Philips maintains a strong footprint in Indonesia, employing over 3,900 people across 12 cities and operating a manufacturing facility in Batam for its Personal Health businesses. The Philips Foundation recently launched a major partnership with World Child Cancer to advance early detection of childhood cancers across the country.

“We remain committed to supporting healthcare transformation by delivering innovations that provide better outcome for patient and improve experience for healthcare workers,” said Astri R. Dharmawan, President Director of Philips Indonesia. “Our combined efforts with the Indonesian government will help close healthcare gaps and bring us closer to a Healthy Indonesia.”

[1] https://www3.weforum.org/docs/WEF_The_Economics_of_non_Disease_Indonesia_2015.pdf
[2] https://pubmed.ncbi.nlm.nih.gov/14746519/

For further information, please contact:

Michael Fuchs
Global External Relations Director, Philips
Tel.: +31 614 869 261
E-mail: michael.fuchs@philips.com

Jane Yeo
Head of Brand and Communications APAC, Philips
Tel.: +65 9618 7397
E-mail: jane.yeo@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.